Table 5 Comparing costs of both arms.

From: Extended infusion of piperacillin–tazobactam versus intermittent infusion in critically ill egyptian patients: a cost-effectiveness study

 

Intermittent infusion (mean ± SD)

Extended infusion (mean ± SD)

P-value

Days of piperacillin-tazobactam therapy

8.9 ± 3.57

5.7 ± 2.07

0.0001

Days until treatment success

8.5 ± 3.2

4.6 ± 0.54

0.026

Total Costs a

$424.93 ± 368.13

(n = 27)

$352.40 ± 187.59

(n = 26)

0.7875

Cost of treatment success

$316.04 ± 103.83

(n = 6)

$146.66 ± 19.40

(n = 5)

0.0061

Cost of treatment failure

$456.04 ± 339.73

(n = 21)

$401.38 ± 175.54

(n = 21)

0.5162

Cost-effectiveness ratio b

$1914.09

$1835.41

 
  1. aTotal cost in USD for preparations, supplies, drugs, and labor was obtained from the hospital during the year 2018–2019b. Cost-effectiveness ratio = mean Total costs/ success rate. P-value ≤ 0.05 is considered statistically significant.
  2. Significant P-values are in bold.
Back to article page